2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2008-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_e2c0fcb64a744e60981ea3944e416a11 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ruperto N |e author |
| 700 | 1 | 0 | |a Quartier P |e author |
| 700 | 1 | 0 | |a Wulffraat N |e author |
| 700 | 1 | 0 | |a Woo P |e author |
| 700 | 1 | 0 | |a Loy A |e author |
| 700 | 1 | 0 | |a Mouy R |e author |
| 700 | 1 | 0 | |a Bader-Meunier B |e author |
| 700 | 1 | 0 | |a Prakken B |e author |
| 700 | 1 | 0 | |a Noseda E |e author |
| 700 | 1 | 0 | |a Rordorf C |e author |
| 245 | 0 | 0 | |a 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) |
| 260 | |b BMC, |c 2008-09-01T00:00:00Z. | ||
| 500 | |a 10.1186/1546-0096-6-S1-S2 | ||
| 500 | |a 1546-0096 | ||
| 546 | |a EN | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 690 | |a Diseases of the musculoskeletal system | ||
| 690 | |a RC925-935 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pediatric Rheumatology Online Journal, Vol 6, Iss Suppl 1, p S2 (2008) | |
| 787 | 0 | |n https://doaj.org/toc/1546-0096 | |
| 856 | 4 | 1 | |u https://doaj.org/article/e2c0fcb64a744e60981ea3944e416a11 |z Connect to this object online. |